326 related articles for article (PubMed ID: 36093924)
1. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.
Targher G; Mantovani A; Byrne CD
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
7. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
Scheen AJ
Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
[TBL] [Abstract][Full Text] [Related]
8. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO; Glotfelty EJ; Li Y; Greig NH
Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
[TBL] [Abstract][Full Text] [Related]
10. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
Conlon JM; O'Harte FPM; Flatt PR
Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
12. Obesity pharmacotherapy: incretin action in the central nervous system.
Boer GA; Hay DL; Tups A
Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
[TBL] [Abstract][Full Text] [Related]
13. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
15. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
16. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
18. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
19. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
20. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.
Andreasen CR; Andersen A; Vilsbøll T
Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
